A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

NCT03840200 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Prostate Cancer
Ovarian Cancer

Interventions

DRUG: Ipatasertib
DRUG: Rucaparib

Sponsor

Hoffmann-La Roche